1. Syntheses of differentially fluorinated triazole-based 1-deoxysphingosine analogues en route to SphK inhibitors.
- Author
-
Cardona A, Ivanova V, Beltrán-Debón R, Barril X, Castillón S, Díaz Y, and Matheu MI
- Subjects
- Humans, Enzyme Inhibitors pharmacology, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Molecular Docking Simulation, Structure-Activity Relationship, Molecular Structure, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors chemical synthesis, Protein Kinase Inhibitors chemistry, Triazoles chemistry, Triazoles pharmacology, Triazoles chemical synthesis, Phosphotransferases (Alcohol Group Acceptor) antagonists & inhibitors, Phosphotransferases (Alcohol Group Acceptor) metabolism, Halogenation, Sphingosine analogs & derivatives, Sphingosine chemistry, Sphingosine pharmacology, Sphingosine chemical synthesis
- Abstract
This study focuses on the stereoselective syntheses of 1-deoxysphingosine analogues as potential inhibitors of sphingosine kinase (SphK), particularly targeting its isoforms SphK1 and SphK2, which are implicated in cancer progression and therapy resistance. The research builds on previous work by designing a series of analogues featuring systematic structural modifications like the incorporation of a triazole ring, varying degrees of fluorination, and different head groups ( e.g. , guanidino, N -methylamino, and N , N -dimethylamino). These modifications aimed to enhance polar and hydrophobic interactions especially with SphK2. The synthesized compounds were evaluated for their inhibitory activity, revealing that certain derivatives, particularly those with guanidino groups and heptafluoropropyl fragments at the lipidic tail, exhibited significant potency and selectivity towards SphK2. Docking studies supported these findings by showing favorable binding interactions within the SphK2 active site, which were less pronounced in SphK1, correlating with the observed selectivity. This work contributes to the development of novel 1-deoxysphingosine analogues targeting SphK inhibition, as well as to the knowledge of the differential topology of the active sites in SphK1 and SphK2.
- Published
- 2025
- Full Text
- View/download PDF